It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SMNDC1 is a Tudor domain protein that recognizes di-methylated arginines and controls gene expression as an essential splicing factor. Here, we study the specific contributions of the SMNDC1 Tudor domain to protein-protein interactions, subcellular localization, and molecular function. To perturb the protein function in cells, we develop small molecule inhibitors targeting the dimethylarginine binding pocket of the SMNDC1 Tudor domain. We find that SMNDC1 localizes to phase-separated membraneless organelles that partially overlap with nuclear speckles. This condensation behavior is driven by the unstructured C-terminal region of SMNDC1, depends on RNA interaction and can be recapitulated in vitro. Inhibitors of the protein’s Tudor domain drastically alter protein-protein interactions and subcellular localization, causing splicing changes for SMNDC1-dependent genes. These compounds will enable further pharmacological studies on the role of SMNDC1 in the regulation of nuclear condensates, gene regulation and cell identity.
SMNDC1 is a splicing factor that binds arginine methylation with its Tudor domain. Here, the authors study the protein’s phase-separating behavior and develop small-molecule Tudor domain inhibitors that perturb SMNDC1 function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802)
2 Institute of Structural Biology, Helmholtz Munich, Molecular Targets and Therapeutics Center, Neuherberg, Germany (GRID:grid.418729.1); Technical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Bavarian NMR Center, Garching, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
3 Institute of Structural Biology, Helmholtz Munich, Molecular Targets and Therapeutics Center, Neuherberg, Germany (GRID:grid.6936.a); Technical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Bavarian NMR Center, Garching, Germany (GRID:grid.6936.a) (ISNI:0000000123222966)
4 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802); Sloan Kettering Institute, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
5 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802); Medical University of Vienna, Institute of Artificial Intelligence, Center for Medical Data Science, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)